Immunologic Mechanisms of Diabetic Ulcers

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (1 December 2022) | Viewed by 290

Special Issue Editors

UICentre for Drug Discovery, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA
Interests: cancer chemoprevention; tumor immunology; innate immunology of diabetic wounds; immunotoxicity; adjuvants
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Surgery, Division of Surgical Oncology, University of Illinois Chicago, Chicago, IL 60612, USA
Interests: cancer therapeutics and cancer immunology; innate immunity; cerebral malaria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetic ulcers are the leading cause of lower limb amputations and also a major healthcare concern throughout the world. The sheer number of diabetic ulcers that progress to amputation underscores the inadequacy of conventional therapies and the need for novel approaches. Therefore, new strategies involving the applications of vaccines or any kind of treatment for controlling diabetic ulcers are urgently needed and development of novel therapeutic approaches to enhance natural host immune defense, i.e., antimicrobial defenses and possibly to stimulate healing in diabetic wounds. This Special Issue aims to give an overview of the most recent advances in the field of therapeutic approaches to control wound infections and promote wound healing. This Special Issue is aimed at providing selected contributions on advances in the therapeutic approaches and applications of immunomodulators to treat diabetic ulcers.

Potential topics include, but are not limited to:

  • Antimicrobial defenses;
  • Immunomodulators strategies;
  • Therapeutic approaches to control infection and promote wound healing;
  • Mechanistic studies;
  • Adverse effects of immunomodulators on wound healing;
  • Identification of the molecular regulators;
  • Identification of targets potentially useful in future clinical trials;
  • Future perspectives for immunomodulators strategies.

We look forward to receiving your contributions.

Dr. Ruchi Roy
Dr. Sunil Singh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic ulcers
  • wound healing
  • vaccine
  • immunomodulators
  • innate immune defense
  • inflammation

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop